As is the case for SARS-CoV and HCoV-NL63, ACE2 is able to bind the SARS-CoV-2 spike (S) protein with high affinity (~ 15 nM) to facilitate host cell infection, and remains a critical therapeutic target that may need to be exploited to combat the virus and its emerging variants15–19. This evidence concerns the gene ACE2 and infection.